Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients (Q3988868): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Fixing summary) |
(Changed an Item: Adding English translations) |
||||||||||||||
| Property / summary | |||||||||||||||
The COVID-19 virus results in a major societal and economic damage worldwide. Many people die of the Corona virus and the pressure on healthcare is immensely high. To combat the pandemic, many countries have put in place a (partial) lockdown. This results in a lower contagion rate but also has significant negative effects on the economy. There is therefore a great need for a vaccine or medicine, preferably orally, for the COVID-19 virus. Hercules Pharmaceuticals works on inhibitors for the Aryl Hydrocarbon Receptor (AhR). The AhR receptor has been identified as an important connecting factor for viral replications. Viruses use the AhR receptor to bypass the immune system and block endogenous mechanisms, preventing viral replications. Together with MercachemSyncom, Hercules Pharmaceuticals will further optimise its lead compound HP163 for COVID-19 towards the clinic. (English) | |||||||||||||||
| Property / summary: The COVID-19 virus results in a major societal and economic damage worldwide. Many people die of the Corona virus and the pressure on healthcare is immensely high. To combat the pandemic, many countries have put in place a (partial) lockdown. This results in a lower contagion rate but also has significant negative effects on the economy. There is therefore a great need for a vaccine or medicine, preferably orally, for the COVID-19 virus. Hercules Pharmaceuticals works on inhibitors for the Aryl Hydrocarbon Receptor (AhR). The AhR receptor has been identified as an important connecting factor for viral replications. Viruses use the AhR receptor to bypass the immune system and block endogenous mechanisms, preventing viral replications. Together with MercachemSyncom, Hercules Pharmaceuticals will further optimise its lead compound HP163 for COVID-19 towards the clinic. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The COVID-19 virus results in a major societal and economic damage worldwide. Many people die of the Corona virus and the pressure on healthcare is immensely high. To combat the pandemic, many countries have put in place a (partial) lockdown. This results in a lower contagion rate but also has significant negative effects on the economy. There is therefore a great need for a vaccine or medicine, preferably orally, for the COVID-19 virus. Hercules Pharmaceuticals works on inhibitors for the Aryl Hydrocarbon Receptor (AhR). The AhR receptor has been identified as an important connecting factor for viral replications. Viruses use the AhR receptor to bypass the immune system and block endogenous mechanisms, preventing viral replications. Together with MercachemSyncom, Hercules Pharmaceuticals will further optimise its lead compound HP163 for COVID-19 towards the clinic. (English) / qualifier | |||||||||||||||
point in time: 15 December 2021
| |||||||||||||||
Revision as of 06:20, 15 December 2021
Project Q3988868 in Netherlands
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients |
Project Q3988868 in Netherlands |
Statements
399,362.0 Euro
0 references
1,055,117.569 Euro
0 references
37.85 percent
0 references
1 June 2020
0 references
1 June 2021
0 references
Hercules Pharmaceuticals
0 references
53°14'32.42"N, 6°31'47.86"E
0 references
52°10'7.79"N, 4°28'2.14"E
0 references
2333BD
0 references
9747AT
0 references
Het COVID-19 virus resulteert wereldwijd in een grote maatschappelijke en economische schade. Tal van mensen overlijden aan het Corona virus en de druk op de gezondheidszorg is immens hoog. Om de pandemie te bestrijden hebben veel landen een (gedeeltelijke) lockdown ingesteld. Dit resulteert in een geringere besmettingsgraad maar heeft ook significante negatieve effecten op de economie. Er is dan ook een grote behoefte aan een vaccin of medicijn, bij voorkeur oraal, voor het COVID-19 virus. Hercules Pharmaceuticals werkt aan inhibitoren voor de Aryl Hydrocarbon Receptor (AhR). De AhR receptor is geïdentificeerd als een belangrijk aanknopingspunt voor virale replicaties. Virussen gebruiken de AhR receptor om het immuunsysteem te omzeilen en endogene mechanismes, die virale replicaties verhinderen, te blokkeren. Samen met het bedrijf MercachemSyncom gaat Hercules Pharmaceuticals haar lead compound HP163 voor COVID-19 verder optimaliseren richting de kliniek. (Dutch)
0 references
The COVID-19 virus results in a major societal and economic damage worldwide. Many people die of the Corona virus and the pressure on healthcare is immensely high. To combat the pandemic, many countries have put in place a (partial) lockdown. This results in a lower contagion rate but also has significant negative effects on the economy. There is therefore a great need for a vaccine or medicine, preferably orally, for the COVID-19 virus. Hercules Pharmaceuticals works on inhibitors for the Aryl Hydrocarbon Receptor (AhR). The AhR receptor has been identified as an important connecting factor for viral replications. Viruses use the AhR receptor to bypass the immune system and block endogenous mechanisms, preventing viral replications. Together with MercachemSyncom, Hercules Pharmaceuticals will further optimise its lead compound HP163 for COVID-19 towards the clinic. (English)
15 December 2021
0 references
Identifiers
OP-2014-2023-Noord-OPSNN0302
0 references